Is BPC-157 Legal in Virginia? How to Access It Legally
From the public record
FDA product listings naming BPC-157
The FDA NDC Directory holds 20 listings naming BPC-157 from 16 firms: 20 bulk ingredient listings and 0 finished product listings, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming BPC-157 | 20 | |
| Bulk ingredient listings | 20 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 8 | |
| Finished product listings | 0 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 16 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains BPC 157 or BPC-157
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
From the public record
FDA drug recalls naming BPC-157
FDA enforcement reports list 6 drug recall entries naming BPC-157 from 2019 to 2025-10-15. 6 of them are for compounded or other unlisted products and 0 for products FDA lists under a label. The most common stated reason was lack of sterility assurance (6 of 6).
| Measure | Value | Note |
|---|---|---|
| Recall entries on record | 6 | |
| For products FDA lists under an approved or registered label | 0 | |
| For compounded or other unlisted products | 6 | matched by the name in the product description |
| Class I (most serious) | 0 | |
| Class II | 6 | |
| Class III | 0 | |
| Most recent recall reported | 2025-10-15 | |
| Most common stated reason | lack of sterility assurance | 6 of 6 entries |
How this was calculated
Counted enforcement report entries matched by FDA's listed active substance, or by the name in the product description where FDA lists none. Reasons were grouped by keywords in FDA's stated reason.
Recalls whose product description names BPC-157, including compounded and multi-ingredient products
Each recall covers specific lots from one firm and is not a statement about every product with this ingredient. One event can appear as several entries, one per product.
From the public record
Registered clinical studies of BPC-157
ClinicalTrials.gov lists 4 registered studies that name BPC-157 as an intervention as of 2026-11-11. Of these, 1 are recruiting, 1 are completed and 0 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 4 |
| Recruiting now | 1 |
| Not yet recruiting | 1 |
| Completed | 1 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 0 |
| Phase 2 (including phase 1/2) | 1 |
| Phase 1 | 2 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches BPC 157 or BPC-157, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
At a glance
- FDA approval / None; no approved product contains BPC-157 [1]
- FDA pharmacy bulks list / Not listed, and not in category 1 [2]
- Outsourcing facilities / Not on FDA's list for large registered compounders [5]
- July 2026 advisory vote / 8 to 6 with 1 abstention in favor of listing; advice only [6][4]
- October 2026 HHS policy / Draft enforcement discretion for certain pharmacies and physicians [3]
- Sport / Named in WADA category S0, prohibited at all times [7]
What FDA has done
BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice. No FDA-approved drug contains it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].
It was in category 2 of FDA's interim compounding policies, the table of bulk substances that may present significant safety risks, from September 2023 until April 22, 2026. It then moved to a withdrawn-nominations table because the groups that nominated it withdrew; that was not a finding of safety [8][4]. FDA's concerns remain posted: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', and the agency 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [8].
BPC-157 is in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, and it is absent from FDA's list for outsourcing facilities [2][5]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it to the pharmacy bulks list, reported as 8 to 6 with 1 abstention, against FDA staff's recommendation. The vote is advice only and BPC-157 is not on the list [6][4].
The October 2026 draft policy
On October 28, 2026 HHS filed a notice announcing a draft enforcement-discretion policy for compounding with six peptides, BPC-157 among them. It is scheduled for Federal Register publication on October 30, 2026, with two weeks of public comment [3][4]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3][4].
For BPC-157 the conditions are: the acetate form only; subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed); a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard; a patient-specific prescription; a label reading 'This is a compounded drug product. Not for resale.'; serious adverse events and quality problems reported to MedWatch; an FDA 510(k)-cleared syringe as the only co-packaged device; and documentation of adequate bioavailability for oral forms [4].
The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public.' HHS may revisit it, for example if a safety signal or product quality issue appears [4]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [4][5].
Other routes people ask about
Websites sell BPC-157 as capsules, injections, oral sprays and nasal sprays, some labeled for research purposes only and not for human or veterinary use. Those products are not FDA-approved drugs [1]. On importation, FDA states that in most circumstances it is illegal for individuals to import drugs for personal use, and that a drug approved in another country but unapproved in the US is illegal to import [9].
What Virginia adds
FDA's and HHS's positions above are federal. The draft policy refers to state-licensed pharmacies and licensed physicians, but it does not establish authorization under Virginia law.
Frequently asked questions
Is BPC-157 legal in Virginia?
Can a Virginia compounding pharmacy fill a BPC-157 prescription?
Did the July 2026 advisory vote make BPC-157 legal to compound?
Is BPC-157 allowed in sport?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Personal Importation | FDA.